Downloads: 1295

Files in This Item:
File Description SizeFormat 
s00280-010-1470-2.pdf153.44 kBAdobe PDFView/Open
Title: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Authors: Kanai, Masashi  kyouindb  KAKEN_id
Yoshimura, Kenichi
Asada, Masanori
Imaizumi, Atsushi
Suzuki, Chihiro
Matsumoto, Shigemi  kyouindb  KAKEN_id
Nishimura, Takafumi
Mori, Yukiko  kyouindb  KAKEN_id
Masui, Toshihiko  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4001-4824 (unconfirmed)
Kawaguchi, Yoshiya  kyouindb  KAKEN_id
Yanagihara, Kazuhiro
Yazumi, Shujiro
Chiba, Tsutomu  kyouindb  KAKEN_id
Guha, Sushovan
Aggarwal, Bharat B
Author's alias: 金井, 雅史
Keywords: Curcumin
Gemcitabine
Pancreatic cancer
Issue Date: Jul-2011
Publisher: Springer-Verlag
Journal title: Cancer chemotherapy and pharmacology
Volume: 68
Issue: 1
Start page: 157
End page: 164
Abstract: Purpose Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy. Methods Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study. Results Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79–100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109–223 days) and 1-year survival rate was 19% (4.4–41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested. Conclusions Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.
Rights: The final publication is available at www.springerlink.com
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/143578
DOI(Published Version): 10.1007/s00280-010-1470-2
PubMed ID: 20859741
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.